A Phase 1, Open-label Dose Escalation and Expansion Study OF PT0511 in Participants With KRAS Mutated OR Amplified Advanced Solid Tumors
Latest Information Update: 30 Dec 2025
At a glance
- Drugs Cetuximab (Primary) ; PT 0511 (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors PAQ Therapeutics
Most Recent Events
- 30 Dec 2025 New trial record